The optimal management of subtotally resected atypical meningiomas is unknown. OBJECTIVE: To perform a retrospective review of patients with residual or recurrent atypical meningiomas treated with stereotactic radiosurgery (SRS). METHODS: Twenty-five patients were treated, either immediately after surgery (n = 15) or at the time of radiographic progression or treatment failure (n = 10). SRS was delivered to with a median marginal dose of 22 Gy (range, 16-30) in 1 to 4 fractions (median, 1), targeting a median tumor volume of 5.3 cm 3 (range, 0.3-26.0).
meningiomas, 5 ,11 many advocate adjuvant radiation for patients with subtotally resected atypical meningiomas because of their high rate of recurrence. [12] [13] [14] Traditionally, the entire tumor bed of a resected atypical meningioma with margin has been irradiated (eg the entire preoperative tumor volume plus a 1-to 3-cm margin, 5, 13 enhancing tumor plus a 3-to 4-cm margin, 6 and operative bed plus 1 cm margin 15 ), often resulting in a large volume of normal brain receiving radiation. Whether these large volumes are necessary is unclear.
Because of its rarity and the recent adaptation of its histological classification, there are limited data on the best adjuvant radiotherapy course for atypical meningiomas. We retrospectively reviewed the outcomes of patients with subtotally resected and recurrent WHO grade II meningiomas treated with stereotactic radiosurgery (SRS) at our institution. Herein, we present our results suggesting that irradiation of the entire tumor bed can be avoided in favor of radiosurgery to treat the residual tumor in well selected patients with subtotally resected atypical meningiomas.
METHODS AND MATERIALS Patients
Patient data were obtained from an institutional review board-approved, prospectively maintained database of patients treated by use of the CyberKnife Robotic Radiosurgical System (Accuray, Sunnyvale, California) at the Stanford University Medical Center. All patients underwent a prior resection and had a histologically confirmed diagnosis of WHO grade II meningioma. 3 Of the 29 patients treated from February 2000 to March 2008, follow-up information was lacking in 4 patients, yielding 25 patients evaluable clinically and radiographically. Five of 25 patients had received prior radiotherapy, yielding 20 radiationna€ Ive patients.
Patient characteristics are listed in Table 1 . Twelve women and 13 men underwent SRS at a median age of 57 years (range, 23-80 years). Ninety-two percent had a Karnofsky performance score of $80%. The median number of prior treatments (surgery and/or radiotherapy) was one (range, 1-9). Patients were referred for SRS treatment at the following times: (1) immediately after surgery because of an area of residual disease seen on postoperative imaging (n = 15 [60%]); (2) at the time of radiographic progression of residual tumor after an initial period of observation following STR (ie, progression of existing tumor) (n = 3 [12%]); (3) for recurrent tumor after surgery and radiation (n = 5 [20%]); or (4) for recurrent tumor after GTR (ie, new tumor formation) (n = 2 [8%]). The initial choice to treat or observe was based on the medical decision making between the patient and the referring physician.
Five patients had prior radiotherapy, including one patient who had both conventionally fractionated external beam radiotherapy (EBRT) (56 Gy) and LINAC-based SRS (18 Gy), 18 and 11 years before receiving CyberKnife SRS. The second patient had received EBRT (54 Gy) 6 months before SRS. Three patients had been treated with SRS alone (ie, no prior EBRT) 7, 39, and 50 months earlier. Patients with prior SRS were referred for additional treatment owing to (1) development of a new tumor within the resection cavity (n = 1), (2) failure at the previously treated target (n = 2), and (3) marginal failure at the posterior border of the previous SRS target (n = 1).
Early SRS was defined as radiosurgery administered shortly after surgery to treat residual tumor seen on postoperative imaging. Late SRS was defined as treatment initiated after evidence of radiographic tumor progression. 
Radiosurgery Dose and Fractionation
The prescribed dose and fractionation schedule were based on the preference of the treating physicians, size of the lesion, proximity of the lesion to nearby critical structures, and dose of prior radiation. Treatment characteristics are listed in Table 1 ). The median maximum dose within the target was 27 Gy (range, 20-39 Gy). SRS was delivered in 1 to 4 fractions (median, 1).
Because of the range in the prescription doses and the fraction schemes used in this series, the biologically effective dose and equivalent single-session dose were derived from the linear quadratic model. 16 Although the a/b ratio for WHO grade II meningiomas is not known, the lower and upper limits of a/b ratio estimates of WHO grade I meningioma have been calculated to be 2.7 to 3.9.
17 Therefore, we selected a conservative a/b ratio estimate of 4 to calculate equivalent single-session doses for WHO grade II lesions. Conversion of the various fractionation schemes used in this series with the linear quadratic formula yielded a median single-session equivalent dose (a/b = 4) of 18 Gy 4 (range, 12-21 Gy 4 ).
Radiosurgical Technique
The CyberKnife Robotic Radiosurgical System (Accuray, Sunnyvale, California) was used to deliver the radiosurgical treatments. A highresolution thin-slice (1.25 mm) computed tomogram was obtained using a GE Light Speed 8i or 16i Scanner (Milwaukee, Wisconsin) after administration of 125 mL of Omnipaque intravenous contrast (iohexol, 350 mg I/mL; Nycomed, Inc., GE Healthcare, Princeton, New Jersey). Stereotactic magnetic resonance imaging (MRI) scan was obtained and fused to the stereotactic CT scan to improve target identification.
The neurosurgeon, radiation oncologist, and radiation physicist performed tumor delineation, dose selection, and planning. The gross tumor volume (GTV) was defined as the residual or recurrent enhanced tumor seen on imaging. The radiosurgical dose was prescribed to cover the GTV, with no additional margin. Treatment plans were generated in an iterative manner using the CyberKnife nonisocentric inverse treatment planning software. An example of a treatment plan is shown in Figure 1 .
Quality of treatment plans was assessed by evaluating target coverage, dose heterogeneity, and conformity. Digitally reconstructed radiograms were computationally synthesized to allow near real-time patient tracking throughout radiosurgery. Informed consent for treatment was obtained for all patients. Patients received 4 mg of dexamethasone immediately after each treatment. For multisession treatments, the typical interfraction time interval was 24 hours.
Follow-up
MRI was repeated at 3-month intervals during the first year following SRS and every 4 to 6 months thereafter. Brain MRI results were used to score local and regional failures. Local failure was defined as progression of the treated lesion (ie, enlargement of existing tumor). Regional failure was defined as a recurrence elsewhere within the resected tumor bed (ie, new tumor within the resection cavity).
Toxicity
Patients were monitored for possible radiation induced adverse events with both clinical follow-up and imaging studies. Toxicity is defined as any unfavorable and unintended change in the sign or symptom considered possibly, probably, or definitely related to SRS. The Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (http:// ctep.cancer.gov) was used for grading of adverse events.
Statistical Analysis
Overall survival, local, regional, and locoregional control rates were calculated using the Kaplan-Meier product-limit method 18 using Stat View, version 5.0.1 (SAS Institute Inc., Cary, North Carolina). The effects of prognostic variables were assessed using the Cox proportional hazards analysis. 19 All factors with a P value of #.2 on univariate analysis were entered into the model. Time of local, regional, and locoregional control rates were calculated from the date of radiosurgery to the last MRI scan that showed recurrence or tumor control. The overall survival rates were calculated from both the date of initial diagnosis and the date of SRS. FIGURE 1. An example of a treatment plan. Thirty Gy in 3 fractions was prescribed to the 80% isodose line to treat a 5.48-cm 3 target. The GTV is shown in shaded gray. Going from the innermost to outermost lines are 80% (white), 70%, 60%, 50%, and 40% isodose lines. GTV, gross tumor volume.
RESULTS

Local and Regional Control
Overall, recurrences were seen in 9 (36%) of 25 patients. Tumor recurred in 3 patients within the targeted region (local failures), in 5 patients with a new tumor elsewhere in the tumor resection bed (regional failures), and in 1 patient both within and outside the radiosurgery target (ie, both local and regional failures). With a median follow-up time of 28 months (range, 3-67 months), the 12-, 24-, and 36-month actuarial local control rates for all patients were 94%, 94%, and 74%, respectively; the 12-, 24-, and 36-month actuarial regional control rates were 90%, 90% and 62%, respectively. The overall, combined locoregional control rates at 12, 24, and 36 months were 90%, 90%, and 47%, respectively ( Figure  2 ). On univariate analysis, the number of recurrences (as a continuous variable) before presenting for CyberKnife SRS (P = .046), early SRS (ie, immediate [within 6 months] postoperative SRS to treat the residual tumor) (P = .03), and age at treatment (as a continuous variable) (P = .04) were predictive of locoregional control. Age $60 years (as a nominal variable) was a significant predictor of locoregional failure (P = .01). Sex, target volume, number of SRS fractions, and biologically effective dose were not significant predictors of recurrence.
Radiation-Na€ Ive Patients
Owing to normal tissue tolerance, prior history of radiotherapy limits the field size and/or prescription dose for subsequent treatments. To eliminate this potentially confounding factor, additional analyses were performed on the 20 patients who presented without prior radiotherapy. Five of the 20 patients were treated because of radiographic evidence of tumor recurrence after an initial period of observation, with a median time from the last surgery to SRS of 22 months (range, 13-46 months). Three of these 5 patients had known residual tumor on postoperative imaging but were observed until tumor progression (ie, enlargement of existing tumor); the other 2 patients had initially been treated with GTR and referred for SRS at the time of tumor recurrence (ie, new tumor formation). The remaining 15 patients were offered upfront SRS owing to the presence of residual tumor on postoperative imaging (median time to SRS of 1 month; range, 1-7 months). The patient characteristics of the radiationna€ Ive group are listed in Table 2 . Recurrence was observed in 5 patients: 2 local and 3 regional failures. With a median follow-up period of 22 months (range, 3-67 months), the actuarial local control rates at 12, 24, and 36 months were 100%, 100%, and 73%, respectively; regional control rates were 93%, 93%, and 75%, respectively. The overall control rates (ie, locoregional) at 12, 24, and 36 months were 93%, 93%, and 54%, respectively ( Figure 3 ).
Recurrences in Radiation-Na€ Ive Patients
Characteristics of the 5 radiation-na€ Ive patients who had recurrences are listed in Table 3 . The median time to recurrence from the date of SRS was 15 months (range, 11-29 months). Two patients had local failures (ie, enlargement of the primary lesions treated with radiosurgery) and received additional treatments: Patient 1 was managed with surgery followed by 60 Gy EBRT using intensity-modulated radiation therapy to treat the tumor bed. Patient 2 underwent a surgical resection, followed by postoperative fractionated CyberKnife SRS to treat a small area of residual tumor (30 Gy in 3 fractions prescribed to the 80% isodose line, targeting a 0.49-cm 3 volume); this patient remains recurrence free at the time of last follow-up, 9 months following the second course of SRS. , and 74%, respectively; the 12-, 24-, and 36-month actuarial regional control rates ([n]) were 90%, 90% and 62%, respectively. The overall locoregional control rates ([+]) at 12, 24, and 36 months were 90%, 90%, and 47%, respectively. SRS, stereotactic radiosurgery. Three patients had regional failures (ie, recurrence of new tumors elsewhere in the resection bed, distant from the radiosurgery target volumes). Patient 3 underwent CyberKnife SRS alone to treat the recurrent tumor (18 Gy in a single session prescribed to the 76% isodose line targeting a 0.5-cm 3 volume); this patient remains free of disease 12 months following the second course of SRS. Patient 4 was managed with surgery followed by postoperative CyberKnife SRS to treat an area of residual tumor; this patient developed another regional recurrence 6 months later and was referred for EBRT. A recurrent tumor located anterior to the prior radiosurgical field was diagnosed in patient 5 on follow-up MRI scan. The patient's recurrent tumor is scheduled to be treated with SRS.
Survival
Overall, 3 of 25 patients have died at the time of this analysis. Calculated from the time of initial diagnosis, with a median follow-up time of 4 years (range, 1.1-21.6 years), the actuarial overall survival rates at 3 and 5 years are 96% and 91%, respectively. Calculated from the time of CyberKnife radiosurgery, the actuarial overall 3-year survival rate is 90% (median follow-up time of 3 years; range, 0.7-9.0 years).
Toxicity
There were 2 cases of radiation-induced adverse events. The first is a case of a grade 1 CNS necrosis in which a follow-up MRI scan showed evidence of radiation necrosis within the bilateral frontal lobe 5 years following SRS. Because the patient was neurologically asymptomatic, no intervention was initiated. The patient continues to be followed closely and is without evidence of tumor progression.
The second is a case of a grade 3 hydrocephalus. Six months following SRS, a patient developed hydrocephalus from obstruction of the fourth ventricle, thought to be due to radiation-induced edema. The patient was treated with an endoscopic third ventriculostomy and remains well without evidence of tumor progression.
DISCUSSION
Atypical (WHO grade II) meningiomas are uncommon and carry a worse prognosis than benign (WHO grade I) lesions. Compared with the 5-year progression-free survival rate of 89% for benign meningiomas, the 5-year progression-free survival rate was 48% for subtotally resected ''malignant'' meningiomas treated with postoperative external beam radiation. 5 Because this study by Goldsmith et al predates the WHO revised grading system, it is not possible to distinguish the outcomes between WHO grade II and III patients. Milosevic et al, 6 also using an older classification system, reviewed 59 patients with atypical (n = 17) or malignant (n = 42) meningiomas treated with postoperative external beam radiation and reported disease progression in 39 patients (66%). Hug et al 15 analyzed 15 patients with atypical meningiomas treated with postoperative radiotherapy; the 5-year actuarial local control rate in their series was 38%.
Surgery is the primary treatment of atypical meningiomas. The extent of surgical resection is important as the reported 10-yearlocal control rates are 87% and 17% after GTR and STR, respectively. 10 Given the high risk of recurrence, adjuvant radiotherapy is advocated for subtotally resected WHO grade II lesions. However, owing to the rarity of atypical meningiomas and the relatively recent adaptation of the histopathologic classification scheme, data are lacking as to the best adjuvant radiation technique, including target definition, dose, and fractionation. Traditionally, large treatment volumes, such as the entire preoperative tumor volume plus a 1-to 3-cm margin, 5, 13 enhancing tumor plus a 3-to 4-cm margin, 6 and operative bed plus 1-cm margin, 15 have been used with conventionally fractionated EBRT to a dose of 50 to 61 Gy. An important issue in irradiating a large brain volume is the risk of late complications, including neurocognitive dysfunction. 20 This issue is especially pertinent in this group of patients with a prolonged life expectancy. In our series, the 5-year overall survival rate, calculated from the time of diagnosis, is 91%. Similarly, high 5-year overall survival rates of 68 to 89% are reported in modern radiotherapy series (Table 4) . Therefore, late sequelae of radiotherapy are a serious concern, and methods to decrease the amount of normal brain being irradiated would appear desirable. Moreover, conventionally fractionated radiotherapy to doses of 50 to 60 Gy causes permanent destruction of the hair follicles, resulting in permanent alopecia. The follicle dose at which 50% of the patients develop permanent alopecia has been calculated to be 43 Gy. 21 The effect of alopecia on patients' quality of life has been better studied in the setting of chemotherapy. Multiple studies have shown alopecia to be one of the most important side effects of cancer treatment, with associated lower scores on quality-of-life measurements, lower self-esteem, poorer body image, decrease in sensuality and sexuality, and reluctance to continue working. 22 To this end, SRS is an attractive option. First, the steep dosegradient away from the target minimizes irradiation of the surrounding normal brain. Second, permanent alopecia is not likely to occur with radiosurgery. 23 Third, the short treatment duration (1-5 days compared with 6 weeks for conventionally fractionated radiation) makes it more convenient for patients and their families, in particular, those living distant from a radiation facility. However, the biggest potential detriment to a patient's health and quality of life is tumor recurrence. Therefore, the use of SRS could not be justified unless the treatment outcomes from SRS are at least comparable to larger field, conventionally fractionated radiotherapy. A selected review of the literature for atypical meningiomas treated with fractionated radiotherapy is shown in Table 4 . The 3-year local and locoregional control rates of 73 and 54% for radiation-na€ Ive patients reported herein compares favorably to the historical outcomes (reported control rates of 34%-68% [5] [6] [7] 13, 15 ) using fractionated EBRT targeting the tumor bed (Table 4) .
The safety and efficacy of SRS has been well established in the treatment of benign meningiomas. [24] [25] [26] Because of its relative rarity, there are fewer published data on the role of SRS in the treatment of WHO grade II meningiomas. A review of SRS literature on treatment of atypical meningiomas is summarized in Table 5 . Because most series report on a heterogeneous group of patients, often combining WHO grade I, II, and/or III lesions and patients with and without prior radiation, it is difficult to evaluate the treatment outcomes of the patients with WHO grade II meningioma separately. The 4-to 5-year overall survival rates of 59 to 91% among patients with atypical meningioma historically achieved with SRS (Table 5) are comparable to the overall survival rates of external beam radiation patients (Table 4) , suggesting no overall survival benefit to large field radiation. Harris and colleagues 27 treated 30 patients (18 atypical and 12 malignant meningiomas) with gamma knife radiosurgery, in combination with surgery and fractionated EBRT. With a median follow-up period of 2.3 years (range, 0.1-11.4 years), the 5-year progression-free survival rate for atypical lesions was 83%; in addition, there was a trend toward improved progression-free survival for patients treated with early SRS (ie, soon after craniotomy rather than waiting until tumor progression). Stafford et al performed gamma knife SRS on 190 patients with meningiomas. Included in the series were 13 atypical and 9 malignant tumors, a majority of which were treated in conjunction with EBRT. The 5-year local control rate for atypical meningiomas was 68%. History of external beam radiation, tumor location, and tumor volume were significant predictors of local failure; however, because benign meningiomas were included in this analysis, it is not possible to ascertain if such factors would be predictive in the setting of atypical meningioma. 26 Huffmann and colleagues 28 treated 21 atypical meningiomas in 15 patients with gamma knife SRS. Four patients had residual tumor, ten had recurrent tumors after 1 to 4 surgeries (median, 2), and one had prior EBRT. The authors report 6 failures, occurring 18 to 36 months following radiation. Recurrences were in the region of the surgical approach or resection bed in 4 patients (27%) and marginal recurrence in 2 (13%). Hakim and coworkers 25 published the results of 155 meningiomas in 127 patients, including 26 atypical meningiomas. Sixty-nine percent had one or more prior treatment, including radiation. For the patients with atypical meningiomas, the median time for freedom from progression was 24.4 months, with a 3-year survival probability of 83%. Mattozo et al reviewed the results of LINAC-based SRS (median marginal dose of 15.5 Gy; range, 12-18 Gy) and stereotactic radiotherapy (SRT) (median dose 49.3 Gy; range, 25-54 Gy) to treat 52 recurrent meningiomas in 25 patients. Included in this were 24 WHO grade II meningiomas in 11 patients; the 3-year progression-free survival rate was 83% (100% and 33% for SRS and SRT treatments, respectively).
In our series of 25 patients with atypical meningioma treated with CyberKnife SRS, 3 factors were predictive of increased risk of locoregional failure. First, the more recurrences a patient had before presenting for CyberKnife SRS, the greater the likelihood of progression after radiosurgery (P = .046). Patients with multiple prior treatment failures were referred to us for SRS because they had few other treatment options remaining. Both tumor biology and tumor hypoxia may contribute to the increased risk of treatment failure. The biology of tumors that are multiply recurrent despite repeated therapies is probably more aggressive and difficult to treat. In addition, prior surgical and radiation effects on the brain's vasculature will create a more hypoxic environment, leading to relative radiation resistance. Second, the tumors that were treated early (ie, within 6 months of craniotomy and before radiographic evidence of tumor progression) had a higher rate of control compared to tumors that were treated at the time of radiographic progression following an initial observation period (P = .03). Similar results were reported by Harris et al 27 in their retrospective analysis of 30 aggressive meningiomas (combination of atypical and malignant lesions) treated with gamma knife radiosurgery. Therefore, we advocate early adjuvant radiotherapy of subtotally resected WHO grade II meningiomas. Finally, improved local control was seen with younger patients (age at treatment #60 years) (P = .01).
A potential disadvantage of omitting tumor bed irradiation is the risk of failure elsewhere inside the resection cavity (ie, regional failure). Little is known about which subset of patients with subtotally resected atypical meningioma would benefit from irradiation of the entire tumor bed. To answer this question, we examined the 20 radiation-na€ Ive patients in our series. Of these, only 3 patients (patients 3, 4, and 5 from Table 3 ) had regional failures (ie, recurrence with a new tumor elsewhere in the resection bed). Therefore, one could argue that these 3 patients may have benefited from upfront tumor bed irradiation. However, even among this group, if the regional recurrence was not multifocal, salvage was achievable with repeat SRS (patients 3 and 5). Tumor bed irradiation should be considered for patients with multifocal recurrence.
It is doubtful that patients 1 and 2 would have benefited from resection tumor bed irradiation given that their treatment failed at the treated targets. Patient 1 eventually underwent external beam radiation at an outside institution. In hindsight, given that patient 1 presented with multifocal tumors, he may not have been an ideal candidate for SRS alone.
We have not routinely irradiated the entire tumor bed for patients presenting after STR of atypical meningiomas. Instead, we have treated only the residual tumor with SRS, after which patients are followed closely with serial imaging. Although the follow-up period is modest, the majority of patients in our series have done well, and importantly, have not required salvage larger volume cranial radiation. Thus far, SRS treatments have been well tolerated, and radiation toxicity has been observed in 2 (8%) of the 25 patients. However, a limitation of the present series is its length of follow-up. Additional toxicity may be encountered with time. A longer follow-up period is necessary to assess the longterm tumor control rate and to confirm safety. More studies are needed to identify the subset of patients who would benefit from tumor bed irradiation. Until then, one must weigh the risk of tumor bed recurrence with long-term neurocognitive effects of irradiating normal brain and tailor treatment recommendations to individual patients. In our experience of subtotally resected atypical meningiomas, early postoperative SRS to treat residual tumor decreases the risk of treatment failure. In addition, foregoing tumor bed irradiation in patients without multifocal disease can result in good local control. In cases of WHO grade II meningiomas treated with GTR, we offer close observation with consideration for SRS at the time of recurrence, with the goal of avoiding early and late side effects of large volume cranial irradiation. As with subtotally resected atypical meningiomas, more studies are needed.
CONCLUSIONS
The optimal adjuvant treatment for resected WHO grade II meningiomas has not been defined. Traditionally, irradiation of the entire tumor bed plus margin has been offered to decrease the risk of recurrence; however, the risk of late neurocognitive toxicity and impact on quality of life with such treatment must be considered in this group of patients with a prolonged life expectancy. Our experience with CyberKnife SRS in patients with subtotally resected WHO grade II meningiomas has shown that early irradiation is associated with lower risk of recurrence compared with waiting until tumor progression. Moreover, these data suggest that in radiation-na€ Ive patients, a large subset of patients can achieve excellent clinical outcomes with SRS alone. More studies are needed to identify patients that may benefit from resection bed irradiation.
Disclosure
